In this prospective, multicenter trial, 140 cirrhotic patients with no previous upper gastrointestinal bleeding and with esophageal varices endoscopically judged to be at high risk of hemorrhage were randomized to receive either sclerotherapy or conservative treatment for the prevention of first var
Prophylactic sclerotherapy in nonalcoholic liver cirrhosis: Preliminary results of a prospective controlled randomized trial
β Scribed by Antonio Russo; Giorgio Giannone; Antonio Magnano; Guido Passanisi; Carmen Longo
- Publisher
- Springer
- Year
- 1989
- Tongue
- English
- Weight
- 487 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0364-2313
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Based on animal studies and pilot studies in humans, betaine, a methyl donor for the remethylation of homocysteine, may be a therapeutic agent for nonalcoholic steatohepatitis (NASH). We evaluated the safety and efficacy of betaine for patients with NASH and whether betaine positively modified facto
Data describing cirrhosis prevalence in the simple steatosis group reported in the study by Rafiq et al. should read NR (not reported) instead of 42 (56.8%). All cirrhosis prevalence proportions were calculated based upon these correct (NR) data.
Propranolol and endoscopic sclerosis of esophageal varices are the two approaches currently used in prophylaxis of the first gastrointestinal hemorrhage in the cirrhotic patient. One hundred twenty-six cirrhotic patients with esophageal varices and no histories of bleeding were included in the trial
Although venovenous bypass (VVBP) has been suggested to protect the kidneys during liver transplantation and its systematic use has therefore been recommended, this beneficial effect of VVBP has not been clearly demonstrated. In a prospective, randomized, controlled trial, 77 patients receiving live